📖

DLB, Parkinson's Disease, and Alzheimer's Disease: Cross-Disease Comparison Matrix

wiki page Created: 2026-04-02 13:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-dementia-lewy-bodies-parki

Related Entities

diseases-dementia-lewy-bodies-parkinsons-alzheimers-comparison

Metadata

slug	diseases-dementia-lewy-bodies-parkinsons-alzheimers-comparison
entity_type	disease
kg_node_id	None

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

Linked Artifacts (1051)

mentions🧪Gamma entrainment therapy to restore hippocampal-cortical sy80%

related🧪HSP90-Tau Disaggregation Complex Enhancement80%

related🧪VCP-Mediated Autophagy Enhancement80%

related🧪LRP1-Dependent Tau Uptake Disruption80%

related🧪Extracellular Vesicle Biogenesis Modulation80%

related🧪Synaptic Vesicle Tau Capture Inhibition80%

related🧪TREM2-mediated microglial tau clearance enhancement80%

related🧪Trans-Synaptic Adhesion Molecule Modulation80%

related🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia80%

related🧪GFAP-Positive Reactive Astrocyte Subtype Delineation80%

related🧪Complement C1QA Spatial Gradient in Cortical Layers80%

related🧪Excitatory Neuron Vulnerability via SLC17A7 Downregulation80%

related🧪APOE Isoform Expression Across Glial Subtypes80%

related🧪ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro80%

related🧪Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli80%

related🧪SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK80%

related🧪Prefrontal sensory gating circuit restoration via PV interne80%

related🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna80%

related🧪Gamma entrainment therapy to restore hippocampal-cortical sy80%

see_also📖Alzheimer's Disease Biomarkers80%

see_also📖ASL Perfusion Biomarkers for Alzheimer's Disease80%

see_also📖Digital Biomarkers for Alzheimer's Disease80%

see_also📖Dried Blood Spot Biomarker Test for Alzheimer's Disease80%

see_also📖DTI Biomarkers for Alzheimer's Disease80%

see_also📖EEG Biomarkers for Alzheimer's Disease80%

see_also📖Eye-Tracking Digital Markers in Alzheimer's Disease80%

see_also📖Gait Biomarkers for Alzheimer's Disease80%

see_also📖GFAP in Alzheimer's Disease80%

see_also📖Inflammatory Biomarkers in Alzheimer's Disease80%

see_also📖Neurogranin - Alzheimer's Disease Biomarker80%

see_also📖Ocular Fluid Biomarkers for Alzheimer's Disease80%

see_also📖Olfactory Biomarkers for Alzheimer's Disease80%

see_also📖Plasma Phospho-Tau Ratio Diagnostic Panel for Alzheimer'80%

see_also📖Salivary Biomarkers for Alzheimer's Disease80%

see_also📖Sleep Biomarkers for Alzheimer's Disease80%

see_also📖Synaptic Biomarkers for Alzheimer's Disease80%

see_also📖Tear Film Biomarkers in Alzheimer's Disease80%

see_also📖Diffuse Amyloid Deposits in Alzheimer's Disease80%

see_also📖ACP-204 for Alzheimer's Disease Psychosis (NCT06159673)80%

see_also📖Adipose-Derived Mesenchymal Stem Cell Therapy for Early Alzh80%

see_also📖ASN90 Phase 2 Trial - Early Alzheimer's Disease (NCT05680%

see_also📖BIIB080 (MAPTRx) Antisense Oligonucleotide for Alzheimer80%

see_also📖BMS-986368 Phase 2 - Agitation in Alzheimer's Disease80%

see_also📖BMS-986446 Phase 2 Trial for Early Alzheimer's Disease80%

see_also📖Cannabidiol for Alzheimer's Disease Prevention (NCT058280%

see_also📖Centella asiatica Phase 1 Trial for Alzheimer's Disease80%

see_also📖EI-1071 Immunomodulator for Alzheimer's Disease (NCT06780%

see_also📖Escitalopram for Agitation in Alzheimer's Disease (NCT080%

see_also📖EX039 Phase 2 (NCT05413655) — Oral Therapeutic for Alzheimer80%

see_also📖ExPlas — Exercise Plasma Transfusion for Alzheimer's Di80%

see_also📖Fasudil for Early Alzheimer's Disease (FEAD) - NCT0636280%

see_also📖[F-18]Flornaptitril PET - Phase 3 for Alzheimer's Disea80%

see_also📖Foralumab Phase 2 Trial for Alzheimer's Disease80%

see_also📖GSK4527226 (AL101) for Early Alzheimer's Disease (NCT0680%

see_also📖Guanfacine NorAD - Phase 3 Trial for Alzheimer's Diseas80%

see_also📖IGC-AD1 for Agitation in Alzheimer's Disease (NCT05543680%

see_also📖ITI-1284 for Alzheimer's Disease Psychosis (NCT0654083380%

see_also📖KarXT (Xanomeline/Trospium) - Phase 3 for Alzheimer's D80%

see_also📖Latrepirdine (DMB-I) Phase 3 Trial for Alzheimer's Dise80%

see_also📖LEAF Trial - THC+CBD for Alzheimer's Disease Agitation 80%

see_also📖NCT03875638 - Levetiracetam for Alzheimer's Disease80%

see_also📖NCT07477431 - Levetiracetam for Persons at Risk for Alzheime80%

see_also📖LHP588: P. gingivalis Targeting for Alzheimer's Disease80%

see_also📖MAR Polypill for Alzheimer's Disease (NCT06597058)80%

see_also📖Masupirdine for Alzheimer's Disease Agitation80%

see_also📖Masupirdine for Agitation in Alzheimer's Disease (NCT0580%

see_also📖MK-2214 for Early Alzheimer's Disease80%

see_also📖Nabilone for Agitation in Alzheimer's Disease (NCT0451680%

see_also📖NAB-IT: Nabilone for Agitation in Alzheimer's Disease80%

see_also📖TRAILBLAZER-ALZ 3 (NCT05026866) — Donanemab for Preclinical 80%

see_also📖GV1001 for Moderate to Severe Alzheimer's Disease (NCT080%

see_also📖Biogen Alzheimer's Disease Phase 2 Trial (NCT05399888)80%

see_also📖TRAILRUNNER-ALZ 1: Remternetug for Early Alzheimer's Di80%

see_also📖CBD (Cannabidiol) for Alzheimer's Disease Agitation - N80%

see_also📖GSK4527226 (AL101) for Early Alzheimer's Disease (NCT0680%

see_also📖The Alzheimer's Disease Tau Platform Clinical Trial (NC80%

see_also📖KarXT for Alzheimer's Disease Cognitive Impairment - MI80%

see_also📖Master Screening Study to Determine Individuals With Potenti80%

see_also📖NRTIs for Alzheimer's Disease - Phase 1 (NCT07210528)80%

see_also📖X/T + X-EC + Lecanemab Phase 2 (NCT07212062) — Alzheimer80%

see_also📖DMB-I (Latrepirdine) Phase 3 (NCT07251023) — Alzheimer'80%

see_also📖Exciva Alzheimer's Disease Phase 2/3 Trial80%

see_also📖NCT06582706: Nicotinic Acid for Alzheimer's Disease80%

see_also📖NCT07262645: Near-Infrared Light Therapy for Mild-Moderate A80%

see_also📖NRTIs for Alzheimer's Disease: Targeting Type-I Interfe80%

see_also📖ONO-2020 for Alzheimer's Disease (NCT06881836)80%

see_also📖NCT06803823 - ONO-2020 for Agitation in Alzheimer's Dis80%

see_also📖Ozanimod for Alzheimer's Disease (NCT06862960)80%

see_also📖Piromelatine 20 mg for Mild Dementia Due to Alzheimer's80%

see_also📖PLX5622 CSF1R Inhibitor Trial in Early Alzheimer's Dise80%

see_also📖Probiotics in Mild Alzheimer's Disease (NCT06181513)80%

see_also📖Recombinant Human Serum Albumin for Alzheimer's Disease80%

see_also📖Senicapoc Alzheimer's Disease Trial - NCT0480424180%

see_also📖SHR-1707 for Alzheimer's Disease (NCT06199037)80%

see_also📖Siponimod for Alzheimer's Disease (NCT06639282)80%

see_also📖SNIFF-Combo: Intranasal Insulin + Empagliflozin for Alzheime80%

see_also📖SToP-AD: Suvorexant for Alzheimer's Disease Prevention80%

see_also📖TRAP-AD: Transcranial Photobiomodulation for Alzheimer'80%

see_also📖VY7523 Phase 1/2 Alzheimer's Disease Trial80%

see_also📖APOE Lipid Metabolism Pathway in Alzheimer's Disease80%

see_also📖CD33 Siglec Receptor Dysfunction Alzheimer's Disease Ca80%

see_also📖Cholinergic System Degeneration in Alzheimer's Disease80%

see_also📖EEG Microstates in Alzheimer's Disease80%

see_also📖Endolysosomal Pathway in Alzheimer's Disease80%

see_also📖Glymphatic System in Alzheimer's Disease80%

see_also📖Locus Coeruleus Degeneration in Alzheimer's Disease80%

see_also📖Metal Ion Homeostasis in Alzheimer's Disease80%

see_also📖Mitochondrial Dysfunction in Alzheimer's Disease Pathwa80%

see_also📖Neuroinflammation in Alzheimer's Disease80%

see_also📖Neuroinflammation Hypothesis in Alzheimer's Disease80%

see_also📖Neurovascular Dysfunction in Alzheimer's Disease: Integ80%

see_also📖NLRP3 Inflammasome Pathway in Alzheimer's Disease80%

see_also📖Sex-Specific Mechanisms in Alzheimer's Disease80%

see_also📖Sporadic Alzheimer's Disease Pathway80%

see_also📖Synaptic Loss in Alzheimer's Disease Pathway80%

see_also📖Tau Kinase-Phosphatase Balance in Alzheimer's Disease80%

see_also📖Ubiquitin-Proteasome System Dysfunction in Alzheimer's 80%

see_also📖Vascular Dementia Mechanisms — Overlap with Alzheimer's80%

see_also📖KarXT for Alzheimer's Disease Cognitive Impairment - MI80%

see_also📖Novartis Alzheimer's Disease Phase 2 Trial (NCT0709451680%

see_also📖Alzheimer's Disease Mechanism Index80%

see_also📖Tau Kinase Signaling Cascade in Alzheimer's Disease80%

see_also📖NPTX1 and NPTXR CSF Markers Predict Alzheimer's Disease80%

see_also📖Speech and Cognitive Biomarkers for Alzheimer's Disease80%

see_also📖VILIP-1 and YKL-40 - Alzheimer's Disease Biomarkers80%

see_also📖Synaptic Therapy Alzheimer's Research Trial (START): A 80%

see_also📖APOE4 and Alzheimer's Disease Risk80%

see_also📖Geniposide for Alzheimer's disease - immune biomarker t80%

see_also📖Sleep and Circadian Dysfunction in Alzheimer's Disease80%

see_also📖A Phase 3, Randomised, Double-blinded, Placebo-controlled St80%

see_also📖Rotigotine and Rivastigmine Combination Therapy for Alzheime80%

mentions🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna79%

mentions🧪Prefrontal sensory gating circuit restoration via PV interne78%

related🧪Gamma entrainment therapy to restore hippocampal-cortical sy72%

related🧪ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro72%

related🧪Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli72%

related🧪SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK72%

related🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna71%

related🧪Prefrontal sensory gating circuit restoration via PV interne71%

mentions🧫Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa70%

mentions🧫Cholinergic System Dysfunction in DLB — Mechanisms and Thera70%

mentions🧫DLB Cognitive Fluctuation Mechanism Experiment70%

mentions🧫Genetic Risk Modifiers in DLB Phenotype70%

mentions🧫Tau Co-Pathology in DLB Clinical Heterogeneity70%

mentions🧫DLB Treatment Response Biomarkers — Predicting Cholinesteras70%

mentions🧪Circadian-Synchronized LRP1 Pathway Activation70%

mentions🧪Synthetic Biology BBB Endothelial Cell Reprogramming70%

mentions🧪Purinergic Signaling Polarization Control70%

mentions🧪Lipid Droplet Dynamics as Phenotype Switches70%

mentions🧪Mechanosensitive Ion Channel Reprogramming70%

related🧫Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa70%

related🧫Cholinergic System Dysfunction in DLB — Mechanisms and Thera70%

related🧫DLB Cognitive Fluctuation Mechanism Experiment70%

related🧫Genetic Risk Modifiers in DLB Phenotype70%

related🧫Tau Co-Pathology in DLB Clinical Heterogeneity70%

related🧫DLB Treatment Response Biomarkers — Predicting Cholinesteras70%

related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%

related🧫Macroautophagy Dysfunction in PD - Experiment Design70%

see_also📖Endosomal-Lysosomal Pathway in Neurodegeneration65%

see_also📖Endosomal Sorting Defects in Neurodegeneration65%

see_also📖Neural Circuit Disruption in Neurodegeneration65%

see_also📖Senescent Cell Clearance in Neurodegeneration65%

related🧫Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa63%

related🧫Cholinergic System Dysfunction in DLB — Mechanisms and Thera63%

related🧫DLB Cognitive Fluctuation Mechanism Experiment63%

related🧫Genetic Risk Modifiers in DLB Phenotype63%

related🧫Tau Co-Pathology in DLB Clinical Heterogeneity63%

related🧫DLB Treatment Response Biomarkers — Predicting Cholinesteras63%

related🧪Circadian-Synchronized LRP1 Pathway Activation63%

related🧪Synthetic Biology BBB Endothelial Cell Reprogramming63%

related🧪Purinergic Signaling Polarization Control63%

related🧪Lipid Droplet Dynamics as Phenotype Switches63%

related🧪Mechanosensitive Ion Channel Reprogramming63%

see_also📖Extracellular Vesicle and Tunneling Nanotube-Mediated Spread60%

see_also📖Antibody Therapy in Neurodegeneration60%

see_also📖Axon Guidance Pathways in Neurodegeneration60%

see_also📖Cerebral Amyloid Angiopathy in Neurodegeneration60%

see_also📖Cerebral Amyloid Angiopathy Pathway in Neurodegeneration60%

see_also📖Convergent Pathways in Neurodegeneration60%

see_also📖COVID-19 Neurodegeneration Mechanism60%

see_also📖Down Syndrome Neurodegeneration Pathway60%

see_also📖Dystrophic Neurites in Neurodegeneration60%

see_also📖Galectin-3 Mechanism in Neurodegeneration60%

see_also📖gp130/IL-6 Family Cytokine Signaling in Neurodegeneration60%

see_also📖HMGB1 Signaling in Neurodegeneration60%

see_also📖IL-1 Signaling Pathway in Neurodegeneration60%

see_also📖Lipid Metabolism Dysregulation in Neurodegeneration60%

see_also📖Microglial Priming Pathway in Neurodegeneration60%

see_also📖Neurovascular Unit Dysfunction in Neurodegeneration60%

see_also📖Peripheral Immune-Brain Crosstalk in Neurodegeneration60%

see_also📖PPAR Signaling Pathway in Neurodegeneration60%

see_also📖Retinal Degeneration Pathway in Neurodegeneration60%

see_also📖RNA-Targeted Therapies in Neurodegeneration60%

see_also📖Sex Differences in Neurodegeneration60%

see_also📖Therapeutic Targets in Neurodegeneration60%

see_also📖Transdiagnostic Proteomic Changes in Neurodegeneration60%

mentions🧫Endothelial CD2AP knockdown effects on memory in male mice60%

mentions🧫SPP1-mediated microglial synaptic engulfment assay60%

mentions🧫CD2AP expression and cognitive decline in AD patients60%

mentions🧫Competing endogenous RNA (ceRNA) network construction60%

mentions🧫Neuroimmune modulation and Aβ clearance mechanisms60%

mentions🧫GWAS of plasma NfL in East Asian cohort60%

mentions🧫Bioinformatics analysis and hub gene identification60%

mentions🧫Network Pharmacology Analysis of Shared AD Targets60%

mentions🧫Cognitive impact of TDP-43 pathology in AD patients60%

mentions🧫Meta-analysis of LRP1 C766T polymorphism and Alzheimer'60%

mentions🧫GWAS of composite biomarker score60%

mentions🧫MRI Phenotyping Method Concordance in Serbian AD Cohort60%

mentions🧫HDAC4 inhibition and NHE6 expression mechanism study60%

mentions🧫Endothelin-1 receptor A antagonist rescue in male CD2AP mice60%

mentions🧫Endothelin-1 receptor A antagonist rescue experiment60%

mentions🧫Reelin treatment rescue via ApoER2 in CD2AP mutant mice60%

mentions🧫SPP1 upregulation in perivascular cells in AD mouse models60%

mentions🧫Amyloid plaque load analysis in triple-mutant mouse brains60%

mentions🧫Plasma ATN biomarkers across AD continuum in Chilean cohort60%

mentions🧫16S rRNA sequencing of gut microbiome in PH-PS treated mice60%

mentions🧫GWAS of plasma pTau217 in East Asian cohort60%

mentions🧫PH-PS treatment in 5×FAD Alzheimer's disease mice60%

mentions🧫SIRPα modulation in mouse models of Alzheimer's disease60%

mentions🧫Dairy intake and dementia risk in Malmö Diet and Cancer coho60%

mentions🧫Spp1 knockout prevents synaptic loss in AD mouse models60%

mentions🧫Creation and validation of 3xAD-ChAT-Cre mouse model60%

mentions🧫In vivo BBB transport of LPS-carrying bEVs60%

mentions🧫Real-world safety study of Lecanemab in Japanese AD patients60%

mentions🧫CHI3L1 variant association with AD progression in human pati60%

mentions🧫Diosmin cognitive rescue in APP/PS1 mice60%

mentions🧫GWAS of plasma pTau181 in East Asian cohort60%

mentions🧫Tet2 modulation in Aβ42-injured mouse hippocampal neurons60%

mentions🧫Behavioral assessment of APP/PSEN1/GD3S triple-mutant mice60%

mentions🧫Immunofluorescence analysis of cerebral microvascular densit60%

mentions🧫Cell-cell interaction analysis of perivascular-microglial cr60%

mentions🧫SAHA@LIPO-ANG2 therapeutic efficacy in 5xFAD mice60%

mentions🧫Adoptive transfer of TCRAβ-Tregs in AD mouse model60%

mentions🧫Chi3l1 deletion in APP/PS1 mouse model of Alzheimer's d60%

mentions🧫CD2AP downregulation in brain endothelial cells - memory fun60%

mentions🧫Transcriptomic profiling and differential expression analysi60%

mentions🧫AAV-mediated Tet2 modulation in 2×Tg-AD mice behavioral stud60%

mentions🧫Single-cell RNA sequencing of microglial states in AD hippoc60%

mentions🧫bEV-mediated synaptic pruning via C1q-C3 pathway60%

mentions🧫AhR agonist effects on NEP expression in N2a cells60%

mentions🧫AhR transcriptional regulation of NEP gene60%

mentions🧫GWAS of plasma GFAP in East Asian cohort60%

mentions🧫AhR agonist effects on NEP in APP/PS1 mice60%

mentions🧫Abeta-induced cell death and aggregation in GD3S-deficient n60%

mentions🧫bEV isolation and LPS quantification from human samples60%

mentions🧫Cerebral blood flow regulation in CD2AP mutant mice60%

mentions🧫Meta-analysis of physical activity interventions on cognitiv60%

mentions🧫Single-nucleus RNA-seq integration analysis60%

mentions🧫Generation of Aβ-specific Tregs using CRISPR-Cas960%

mentions🧫qPCR and western blot analysis of microvascular functional m60%

mentions🧫Reelin glycoprotein treatment rescue experiment60%

mentions🧫bEV extraction and analysis from mouse samples60%

mentions🧫KEEPS Continuation: Long-term effects of menopausal hormone 60%

mentions🧫Summary-based Mendelian randomization analysis60%

mentions🧫Anti-ASC antibody intracerebroventricular injection in APP/P60%

mentions🧫ASC antibody treatment in SH-SY5Y-APP695 cells60%

mentions🧫Tet2 expression analysis in aged 2×Tg-AD mouse brains60%

mentions🧫Morphological characterization of microglial states in human60%

mentions🧫Microglial SIRPα expression in human Alzheimer's diseas60%

mentions🧫APOE4 association with TDP-43 pathology in AD60%

mentions🧫Microglial activation by bEVs via Piezo160%

mentions🧫Curcumin-Licorice Combination in D-galactose/Sodium Nitrite 60%

mentions🧫Cerebrovascular function analysis in CD2AP mutant mice60%

mentions🧫CD2AP loss association with cognitive decline in AD patients60%

mentions🧫TDP-43 pathology prevalence and distribution in AD cases60%

mentions🧪ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro60%

mentions🧪SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK60%

mentions🧫Longitudinal TLR2 reporter gene study in α-synuclein mice60%

mentions🧫iPSC-derived astrocyte-neuron co-culture mitochondrial trans60%

mentions🧫TLR expression in α-synuclein overexpressing mice60%

mentions🧫TLR expression analysis in Parkinson's disease patients60%

mentions🧫Dexamethasone treatment study in α-synuclein mice60%

mentions🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia60%

mentions🧪GFAP-Positive Reactive Astrocyte Subtype Delineation60%

mentions🧪Complement C1QA Spatial Gradient in Cortical Layers60%

mentions🧪Excitatory Neuron Vulnerability via SLC17A7 Downregulation60%

mentions🧪APOE Isoform Expression Across Glial Subtypes60%

mentions🧪Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli60%

related🧫s:** - Test whether HCN1 knockout specifically in EC layer I60%

related🧫Proposed experiment from debate on Synaptic pruning by micro60%

related🧫Brain Connectivity-Targeted tACS Trial in Early AD60%

related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 60%

related🧫4R-Tau Targeting Therapies for PSP and CBS60%

related🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi60%

related🧫AD Combination Therapy Trial: Anti-Aβ + Anti-Tau60%

related🧫Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti60%

related🧫Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?60%

related🧫Animal Model Comparison for Neurodegenerative Disease Therap60%

related🧫Anti-Tau Immunotherapy Dosing Optimization60%

related🧫ApoE4 Function in Alzheimer's Disease60%

related🧫Experiment: Autoimmune Hypothesis Testing in AD60%

related🧫Autophagy Enhancement Drug Screening for Neurodegeneration60%

related🧫Biomarker-Guided Sequential Therapy Selection in Alzheimer&#60%

related🧫Blood-Based Biomarker Panel for Early AD Detection60%

related🧫tACS Connectivity Trial in Early Alzheimer's60%

related🧫Brain Connectivity-Targeted tACS Trial in Early AD60%

related🧫Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated 60%

related🧫Cognitive Reserve Mechanisms in Alzheimer's Disease — M60%

related🧫Down Syndrome Alzheimer's Disease: Mechanisms and Thera60%

related🧫Epigenetic Regulation Dysfunction in Alzheimer's and Pa60%

related🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation60%

related🧫Gap Junction Dysfunction Validation in Parkinson's Dise60%

related🧫Lifestyle Intervention Mechanisms in Alzheimer's Diseas60%

related🧫Metal Ion Homeostasis Dysregulation in Alzheimer's Dise60%

related🧫Microbiome-Gut-Brain Axis in Alzheimer's Disease — mech60%

related🧫Microglial Aging and Immune Memory in Neurodegeneration — Tr60%

related🧫Migraine Cortical Hyperexcitability and Alzheimer's Dis60%

related🧫Mixed Pathology Effects on Parkinson's Disease Progress60%

related🧫Neural Stem Cell Therapy for Alzheimer's Disease60%

related🧫Normal Aging to Alzheimer's Disease Transition Trigger 60%

related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 60%

related🧫Prion Strain Diversity and Selective Vulnerability60%

related🧫SCFA-Mediated Neuroinflammation in Alzheimer's Disease60%

related🧫Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer&#60%

related🧫Sex Differences in Alzheimer's Disease — mechanisms and60%

related🧫Sleep Disruption and Alzheimer's Disease — mechanism an60%

related🧫Traumatic Brain Injury and Alzheimer's Disease Relation60%

related🧫Experiment Validation: In vitro ThT Assay60%

related🧫Tau ASO Therapy60%

related🧫Microglial TREM2 Agonist In Vivo Efficacy60%

related🧫TREM2 Function in Alzheimer's Disease — From Risk Varia60%

related🧫Vascular Contribution to Alzheimer's Disease — Beyond A60%

related🧫Vascular Contributions to Alzheimer Disease and Mixed Pathol60%

related🧫Viral Infections and Alzheimer's Disease — causal mecha60%

related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera60%

related🧫AAV-LRRK2 IND-Enabling Study Design60%

related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD60%

related🧫Alpha-Synuclein SAA Kinetics Study — Biological Staging Back60%

related🧫Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio60%

related🧫Computational Modeling of Alpha-Synuclein Propagation in PD60%

related🧫Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation60%

related🧫Alpha-Synuclein Seed Amplification Assay Validation60%

related🧫Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation60%

related🧫Antiviral Therapy Trial for Parkinson's Disease60%

related🧫Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson&60%

related🧫Axonal Transport Dysfunction Validation in Parkinson's 60%

related🧫cGAS-STING Pathway Validation Study in Parkinson's Dise60%

related🧫Chaperone-Mediated Autophagy Dysfunction in PD - Experiment 60%

related🧫Combination Therapy Sequencing in Parkinson's Disease60%

related🧫CRISPR Gene Correction Approaches for CBS/PSP60%

related🧫DNA Damage Repair Deficiency Validation Study in Parkinson&#60%

related🧫Mechanism: Selective Vulnerability of Dopaminergic Neurons i60%

related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#60%

related🧫Epigenetic Dysregulation Validation in Parkinson's Dise60%

related🧫Exercise-BDNF-Mitophagy Biomarker Study in PD60%

related🧫Ferroptosis Validation in Parkinson's Disease60%

related🧫GLP-1 Agonist Neuroprotection Mechanism in PD60%

related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&60%

related🧫Gut-Brain Axis Pathogenesis in Parkinson's Disease — Me60%

related🧫Cytochrome Therapeutics60%

related🧫Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson60%

related🧫Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown60%

related🧫AAV-LRRK2 Gene Therapy IND-Enabling Study Design60%

related🧫LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne60%

related🧫Validate Mitochondria-Lysosome Contact Site Dysfunction in P60%

related🧫Validation: Membrane-Nucleation in iPSC Neurons60%

related🧫Metabolic Syndrome-Parkinson's Disease Axis Clinical Tr60%

related🧫Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in 60%

related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag60%

related🧫MLCS Quantification in Parkinson's Disease60%

related🧫Experiment: Multi-Ethnic PD GWAS60%

related🧫Multiscale Computational Modeling of Protein Aggregation Kin60%

related🧫Neural Oscillation Dysfunction Validation in Parkinson'60%

related🧫NLRP3 Inflammasome Validation Study in Parkinson's Dise60%

related🧫Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper60%

related🧫Non-Motor Symptom Progression in Parkinson's Disease — 60%

related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#60%

related🧫Parkinson's Disease Subtype Classification — Precision 60%

related🧫Peroxisomal Dysfunction Validation in Parkinson's Disea60%

related🧫Peroxisome Dysfunction Validation in Parkinson's Diseas60%

related🧫Prodromal Parkinson's Disease Biomarker Development — E60%

related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin60%

related🧫Purinergic Signaling Dysfunction Validation in Parkinson60%

related🧫Regulated Necrosis Validation Study in Parkinson's Dise60%

related🧫Sirtuin Dysfunction Validation in Parkinson's Disease60%

related🧫Sirtuin Pathway Dysfunction Validation in Parkinson's D60%

related🧫Stress Granule Dysfunction Validation in Parkinson's Di60%

related🧫Synaptic Mitochondrial Resilience Enhancement for Parkinson&60%

related🧫Synaptic Vesicle Trafficking Dysfunction Validation in Parki60%

related🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim60%

mentions🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer55%

mentions🧪Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides55%

mentions🧪Competitive APOE4 Domain Stabilization Peptides55%

mentions🧫s:** - Test whether HCN1 knockout specifically in EC layer I55%

mentions🧫Proposed experiment from debate on Synaptic pruning by micro55%

mentions🧫Brain Connectivity-Targeted tACS Trial in Early AD55%

mentions🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 55%

mentions🧫4R-Tau Targeting Therapies for PSP and CBS55%

mentions🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi55%

mentions🧫AD Combination Therapy Trial: Anti-Aβ + Anti-Tau55%

mentions🧫Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti55%

mentions🧫Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?55%

mentions🧫Animal Model Comparison for Neurodegenerative Disease Therap55%

mentions🧫Anti-Tau Immunotherapy Dosing Optimization55%

mentions🧫ApoE4 Function in Alzheimer's Disease55%

mentions🧫Experiment: Autoimmune Hypothesis Testing in AD55%

mentions🧫Autophagy Enhancement Drug Screening for Neurodegeneration55%

mentions🧫Biomarker-Guided Sequential Therapy Selection in Alzheimer&#55%

mentions🧫Blood-Based Biomarker Panel for Early AD Detection55%

mentions🧫tACS Connectivity Trial in Early Alzheimer's55%

mentions🧫Brain Connectivity-Targeted tACS Trial in Early AD55%

mentions🧫Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated 55%

mentions🧫Cognitive Reserve Mechanisms in Alzheimer's Disease — M55%

mentions🧫Down Syndrome Alzheimer's Disease: Mechanisms and Thera55%

mentions🧫Epigenetic Regulation Dysfunction in Alzheimer's and Pa55%

mentions🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation55%

mentions🧫Gap Junction Dysfunction Validation in Parkinson's Dise55%

mentions🧫Lifestyle Intervention Mechanisms in Alzheimer's Diseas55%

mentions🧫Metal Ion Homeostasis Dysregulation in Alzheimer's Dise55%

mentions🧫Microbiome-Gut-Brain Axis in Alzheimer's Disease — mech55%

mentions🧫Microglial Aging and Immune Memory in Neurodegeneration — Tr55%

mentions🧫Migraine Cortical Hyperexcitability and Alzheimer's Dis55%

mentions🧫Mixed Pathology Effects on Parkinson's Disease Progress55%

mentions🧫Neural Stem Cell Therapy for Alzheimer's Disease55%

mentions🧫Normal Aging to Alzheimer's Disease Transition Trigger 55%

mentions🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 55%

mentions🧫Prion Strain Diversity and Selective Vulnerability55%

mentions🧫SCFA-Mediated Neuroinflammation in Alzheimer's Disease55%

mentions🧫Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer&#55%

mentions🧫Sex Differences in Alzheimer's Disease — mechanisms and55%

mentions🧫Sleep Disruption and Alzheimer's Disease — mechanism an55%

mentions🧫Traumatic Brain Injury and Alzheimer's Disease Relation55%

mentions🧫Experiment Validation: In vitro ThT Assay55%

mentions🧫Tau ASO Therapy55%

mentions🧫Microglial TREM2 Agonist In Vivo Efficacy55%

mentions🧫TREM2 Function in Alzheimer's Disease — From Risk Varia55%

mentions🧫Vascular Contribution to Alzheimer's Disease — Beyond A55%

mentions🧫Vascular Contributions to Alzheimer Disease and Mixed Pathol55%

mentions🧫Viral Infections and Alzheimer's Disease — causal mecha55%

mentions🧫AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera55%

mentions🧫AAV-LRRK2 IND-Enabling Study Design55%

mentions🧫AAV Serotype Comparison for LRRK2 Knockdown in PD55%

mentions🧫Alpha-Synuclein SAA Kinetics Study — Biological Staging Back55%

mentions🧫Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio55%

mentions🧫Computational Modeling of Alpha-Synuclein Propagation in PD55%

mentions🧫Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation55%

mentions🧫Alpha-Synuclein Seed Amplification Assay Validation55%

mentions🧫Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation55%

mentions🧫Antiviral Therapy Trial for Parkinson's Disease55%

mentions🧫Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson&55%

mentions🧫Axonal Transport Dysfunction Validation in Parkinson's 55%

mentions🧫cGAS-STING Pathway Validation Study in Parkinson's Dise55%

mentions🧫Chaperone-Mediated Autophagy Dysfunction in PD - Experiment 55%

mentions🧫Combination Therapy Sequencing in Parkinson's Disease55%

mentions🧫CRISPR Gene Correction Approaches for CBS/PSP55%

mentions🧫DNA Damage Repair Deficiency Validation Study in Parkinson&#55%

mentions🧫Mechanism: Selective Vulnerability of Dopaminergic Neurons i55%

mentions🧫Endocannabinoid System Dysfunction Validation in Parkinson&#55%

mentions🧫Epigenetic Dysregulation Validation in Parkinson's Dise55%

mentions🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De55%

mentions🧫Exercise-BDNF-Mitophagy Biomarker Study in PD55%

mentions🧫Ferroptosis Validation in Parkinson's Disease55%

mentions🧫GLP-1 Agonist Neuroprotection Mechanism in PD55%

mentions🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&55%

mentions🧫Gut-Brain Axis Pathogenesis in Parkinson's Disease — Me55%

mentions🧫Cytochrome Therapeutics55%

mentions🧫Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson55%

mentions🧫Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown55%

mentions🧫AAV-LRRK2 Gene Therapy IND-Enabling Study Design55%

mentions🧫LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne55%

mentions🧫Macroautophagy Dysfunction in PD - Experiment Design55%

mentions🧫Validate Mitochondria-Lysosome Contact Site Dysfunction in P55%

mentions🧫Validation: Membrane-Nucleation in iPSC Neurons55%

mentions🧫Metabolic Syndrome-Parkinson's Disease Axis Clinical Tr55%

mentions🧫Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in 55%

mentions🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag55%

mentions🧫MLCS Quantification in Parkinson's Disease55%

mentions🧫Experiment: Multi-Ethnic PD GWAS55%

mentions🧫Multiscale Computational Modeling of Protein Aggregation Kin55%

mentions🧫Neural Oscillation Dysfunction Validation in Parkinson'55%

mentions🧫NLRP3 Inflammasome Validation Study in Parkinson's Dise55%

mentions🧫Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper55%

mentions🧫Non-Motor Symptom Progression in Parkinson's Disease — 55%

mentions🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#55%

mentions🧫Parkinson's Disease Subtype Classification — Precision 55%

mentions🧫Peroxisomal Dysfunction Validation in Parkinson's Disea55%

mentions🧫Peroxisome Dysfunction Validation in Parkinson's Diseas55%

mentions🧫Prodromal Parkinson's Disease Biomarker Development — E55%

mentions🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin55%

mentions🧫Purinergic Signaling Dysfunction Validation in Parkinson55%

mentions🧫Regulated Necrosis Validation Study in Parkinson's Dise55%

mentions🧫Sirtuin Dysfunction Validation in Parkinson's Disease55%

mentions🧫Sirtuin Pathway Dysfunction Validation in Parkinson's D55%

mentions🧫Stress Granule Dysfunction Validation in Parkinson's Di55%

mentions🧫Synaptic Mitochondrial Resilience Enhancement for Parkinson&55%

mentions🧫Synaptic Vesicle Trafficking Dysfunction Validation in Parki55%

mentions🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim55%

see_also📖Cell-Free DNA Biomarkers in Neurodegeneration55%

see_also📖Exosomal Biomarkers in Neurodegeneration55%

see_also📖Exosomal miR-155 in Neurodegeneration55%

see_also📖IL-6 (Interleukin-6) in Neurodegeneration55%

see_also📖Liquid Biopsy in Neurodegeneration55%

see_also📖Metabolomic Biomarkers in Neurodegeneration55%

see_also📖Neuroimaging Biomarkers for Neurodegeneration55%

see_also📖Synaptic Biomarkers in Neurodegeneration55%

see_also📖BEACoN Study - Biomarker Exploration in Aging, Cognition and55%

see_also📖Olfactory Mucosa, Blood and Urine for Identification of Earl55%

see_also📖Swedish BioFINDER 2 Study: Biomarkers and Neurodegeneration 55%

see_also📖Beta-Propeller Protein-Associated Neurodegeneration (BPAN)55%

see_also📖Cross-National Cancer-Dementia Correlation and Shared Diseas55%

see_also📖Cancer-Dementia Inverse Correlation: Epidemiological Evidenc55%

see_also📖China Neurodegeneration Epidemiology55%

see_also📖DALY Methodology — Neurodegeneration55%

see_also📖Disease Progression & Staging in Neurodegeneration55%

see_also📖Economic Burden — Neurodegeneration55%

see_also📖European Neurodegeneration Epidemiology55%

see_also📖Familial vs Sporadic Neurodegeneration Comparison55%

see_also📖Global Neurodegeneration Epidemiology55%

see_also📖India Neurodegeneration Epidemiology55%

see_also📖Japan Neurodegeneration Epidemiology55%

see_also📖Manganese-Related Neurodegeneration (Manganism)55%

see_also📖mitochondrial-dysfunction-neurodegeneration-comparison55%

see_also📖Mitochondrial Diseases and Neurodegeneration Comparison Matr55%

see_also📖Mitochondrial Membrane Protein-Associated Neurodegeneration 55%

see_also📖Neurodegeneration with Brain Iron Accumulation (NBIA)55%

see_also📖Potential Impact Measures — Neurodegeneration55%

see_also📖Pantothenate Kinase-Associated Neurodegeneration (PKAN)55%

see_also📖PLA2G6-Associated Neurodegeneration (PLAN)55%

see_also📖Sleep Disorders in Neurodegeneration55%

see_also📖US Neurodegeneration Epidemiology55%

see_also📖ABCA7 Lipid Transport and Microglial Phagocytosis AD Causal 55%

see_also📖acetylcholine-signaling-neurodegeneration55%

see_also📖Advanced Glycation End Products in Neurodegeneration55%

see_also📖Advanced In Vitro Models for Neurodegeneration — Organoids, 55%

see_also📖Amylin Signaling in Neurodegeneration55%

see_also📖Antisense Oligonucleotide (ASO) Therapy in Neurodegeneration55%

see_also📖Autosis Pathway in Neurodegeneration55%

see_also📖Basal Ganglia Circuit Dysfunction in Neurodegeneration55%

see_also📖Blood-Brain Barrier and Neuroimmune Interface in CBS/PSP55%

see_also📖becn1-autophagy-initiation-neurodegeneration-causal-chain55%

see_also📖CaMKII Signaling Pathway in Neurodegeneration55%

see_also📖Carbonic Anhydrase Modulator Therapy in Neurodegeneration55%

see_also📖Cholinergic System Dysfunction in Neurodegeneration55%

see_also📖Chrononutrition and Time-Restricted Eating in Neurodegenerat55%

see_also📖Neural Circuits in Neurodegeneration55%

see_also📖Cognitive Reserve and Resilience in Neurodegeneration55%

see_also📖Computational Disease Models for Neurodegeneration55%

see_also📖Copper Homeostasis in Neurodegeneration55%

see_also📖Diffusion MRI (DTI) in Neurodegeneration55%

see_also📖Digital Phenotyping in Neurodegeneration55%

see_also📖Endocannabinoid System in Neurodegeneration55%

see_also📖Endothelin Signaling Pathway in Neurodegeneration55%

see_also📖epigenetics-neurodegeneration55%

see_also📖ESCRT-III Inhibition by Alpha-Synuclein in Neurodegeneration55%

see_also📖FA2H-Associated Neurodegeneration Pathway55%

see_also📖Farnesoid X Receptor (FXR) Signaling in Neurodegeneration55%

see_also📖Gangliosides in Neurodegeneration55%

see_also📖GDF15/GDF11 Signaling in Neurodegeneration55%

see_also📖GDNF Signaling Pathway in Neurodegeneration55%

see_also📖Ghrelin Signaling Pathway in Neurodegeneration55%

see_also📖Glucocorticoid Signaling Pathway in Neurodegeneration55%

see_also📖Glycosylation in Neurodegeneration55%

see_also📖Hippocampal Neurogenesis in Neurodegeneration55%

see_also📖Histone Modification Pathways in Neurodegeneration55%

see_also📖Homocysteine Neurotoxicity and Neurodegeneration55%

see_also📖IGF-1 Signaling Pathway in Neurodegeneration55%

see_also📖Integrated Stress Response in Neurodegeneration55%

see_also📖interleukin-6-signaling-neurodegeneration55%

see_also📖Intrinsic Apoptosis Pathway in Neurodegeneration55%

see_also📖Ion Channel Dysfunction in Neurodegeneration: Cross-Disease 55%

see_also📖Kidney-Brain Neurodegeneration Axis55%

see_also📖Lipid Dysregulation in Neurodegeneration55%

see_also📖Lysosomal Calcium Dysregulation in Neurodegeneration55%

see_also📖Magnetic Resonance Spectroscopy in Neurodegeneration55%

see_also📖Metal Homeostasis Dysregulation in Neurodegeneration55%

see_also📖Metal Homeostasis in Neurodegeneration55%

see_also📖MicroRNA Dysfunction in Neurodegeneration55%

see_also📖Mineralocorticoid Receptor Signaling in Neurodegeneration55%

see_also📖Mitochondrial Dynamics Pathway in Neurodegeneration55%

see_also📖Mitochondrial Fusion in Neurodegeneration55%

see_also📖Molecular Chaperones in Neurodegeneration55%

see_also📖mTOR Signaling in Neurodegeneration55%

see_also📖mTOR Signaling Pathway in Neurodegeneration55%

see_also📖Neurexin/Neuroligin Synaptic Adhesion Modulator Therapy in N55%

see_also📖Neurofilament Light Chain (NfL) Mechanism in Neurodegenerati55%

see_also📖Neuronal Hyperexcitability in Neurodegeneration55%

see_also📖Neuropil Threads in Neurodegeneration55%

see_also📖Neurotensin Signaling in Neurodegeneration55%

see_also📖NF-kB Signaling Pathway in Neurodegeneration55%

see_also📖Nitric Oxide Signaling in Neurodegeneration55%

see_also📖Noradrenergic Signaling Pathway in Neurodegeneration55%

see_also📖Neuropeptide Y Signaling in Neurodegeneration55%

see_also📖NRF2 Signaling Pathway in Neurodegeneration55%

see_also📖Nuclear Pore Complex Dysfunction in Neurodegeneration55%

see_also📖Orexin Signaling in Neurodegeneration55%

see_also📖OSK Reprogramming and Yamanaka Factors in Neurodegeneration55%

see_also📖P-Body (Processing Body) Pathway in Neurodegeneration55%

see_also📖Paranodal Dysfunction in Neurodegeneration55%

see_also📖Paraptosis in Neurodegeneration55%

see_also📖Parthanatos in Neurodegeneration55%

see_also📖Pericyte Loss in Neurodegeneration55%

see_also📖PKR Pathway in Neurodegeneration55%

see_also📖Prion Diseases in Neurodegeneration55%

see_also📖Prion-Like Spread in Neurodegeneration55%

see_also📖Prion Protein Metabolism in Neurodegeneration55%

see_also📖Progesterone Signaling Pathway in Neurodegeneration55%

see_also📖Prognostic Biomarkers in Neurodegeneration55%

see_also📖Protein Aggregation Comparison in Neurodegeneration55%

see_also📖Protein Aggregation Seeds in Neurodegeneration55%

see_also📖Protein O-GlcNAcylation Pathway in Neurodegeneration55%

see_also📖Cortical Involvement and Neurodegeneration in Progressive Su55%

see_also📖Purinergic Signaling in Neurodegeneration55%

see_also📖Quantum Biology and Coherent Energy Transfer in Neurodegener55%

see_also📖R-Loop Stress in Neurodegeneration55%

see_also📖RAN Translation in Neurodegeneration55%

see_also📖Ribosome Dysfunction in Neurodegeneration55%

see_also📖RNA Splicing in Neurodegeneration55%

see_also📖Ribonuclease κ and Circular RNAs: A New Mechanism of Aging a55%

see_also📖S100 Protein Signaling Pathway in Neurodegeneration55%

see_also📖Serotonergic Dysfunction in Neurodegeneration55%

see_also📖Short Chain Fatty Acids in Neurodegeneration55%

see_also📖Sigma-1 Receptor Signaling in Neurodegeneration55%

see_also📖Sirtuin-Mitochondrial Biogenesis Axis in Neurodegeneration55%

see_also📖Sleep Dysfunction in Neurodegeneration55%

see_also📖SUMOylation in Neurodegeneration55%

see_also📖synaptic-vesicle-cycling-neurodegeneration55%

see_also📖Synthetic Lethality and PARP Inhibition in Neurodegeneration55%

see_also📖T-Cell Dysfunction in Neurodegeneration55%

see_also📖Tertiary Lymphoid Organs in Neurodegeneration55%

see_also📖ubiquitin-proteasome-dysfunction-neurodegeneration55%

see_also📖Ubiquitin-Proteasome System Dysfunction in Neurodegeneration55%

see_also📖Vagus Nerve Pathway in Neurodegeneration55%

see_also📖VEGF Signaling and Cerebral Angiogenesis in Neurodegeneratio55%

see_also📖vip-vasoactive-intestinal-peptide-signaling-neurodegeneratio55%

see_also📖WNK1-Bilirubin Signaling in Neuroinflammation and Neurodegen55%

see_also📖Wnt/β-Catenin Signaling Pathway in Neurodegeneration55%

related🧫Endothelial CD2AP knockdown effects on memory in male mice54%

related🧫SPP1-mediated microglial synaptic engulfment assay54%

related🧫CD2AP expression and cognitive decline in AD patients54%

related🧫Competing endogenous RNA (ceRNA) network construction54%

related🧫Neuroimmune modulation and Aβ clearance mechanisms54%

related🧫GWAS of plasma NfL in East Asian cohort54%

related🧫Bioinformatics analysis and hub gene identification54%

related🧫Network Pharmacology Analysis of Shared AD Targets54%

related🧫Cognitive impact of TDP-43 pathology in AD patients54%

related🧫Meta-analysis of LRP1 C766T polymorphism and Alzheimer'54%

related🧫GWAS of composite biomarker score54%

related🧫MRI Phenotyping Method Concordance in Serbian AD Cohort54%

related🧫HDAC4 inhibition and NHE6 expression mechanism study54%

related🧫Endothelin-1 receptor A antagonist rescue in male CD2AP mice54%

related🧫Endothelin-1 receptor A antagonist rescue experiment54%

related🧫Reelin treatment rescue via ApoER2 in CD2AP mutant mice54%

related🧫SPP1 upregulation in perivascular cells in AD mouse models54%

related🧫Amyloid plaque load analysis in triple-mutant mouse brains54%

related🧫Plasma ATN biomarkers across AD continuum in Chilean cohort54%

related🧫16S rRNA sequencing of gut microbiome in PH-PS treated mice54%

related🧫GWAS of plasma pTau217 in East Asian cohort54%

related🧫PH-PS treatment in 5×FAD Alzheimer's disease mice54%

related🧫SIRPα modulation in mouse models of Alzheimer's disease54%

related🧫Dairy intake and dementia risk in Malmö Diet and Cancer coho54%

related🧫Spp1 knockout prevents synaptic loss in AD mouse models54%

related🧫Creation and validation of 3xAD-ChAT-Cre mouse model54%

related🧫In vivo BBB transport of LPS-carrying bEVs54%

related🧫Real-world safety study of Lecanemab in Japanese AD patients54%

related🧫CHI3L1 variant association with AD progression in human pati54%

related🧫Diosmin cognitive rescue in APP/PS1 mice54%

related🧫GWAS of plasma pTau181 in East Asian cohort54%

related🧫Tet2 modulation in Aβ42-injured mouse hippocampal neurons54%

related🧫Behavioral assessment of APP/PSEN1/GD3S triple-mutant mice54%

related🧫Immunofluorescence analysis of cerebral microvascular densit54%

related🧫Cell-cell interaction analysis of perivascular-microglial cr54%

related🧫SAHA@LIPO-ANG2 therapeutic efficacy in 5xFAD mice54%

related🧫Adoptive transfer of TCRAβ-Tregs in AD mouse model54%

related🧫Chi3l1 deletion in APP/PS1 mouse model of Alzheimer's d54%

related🧫CD2AP downregulation in brain endothelial cells - memory fun54%

related🧫Transcriptomic profiling and differential expression analysi54%

related🧫AAV-mediated Tet2 modulation in 2×Tg-AD mice behavioral stud54%

related🧫Single-cell RNA sequencing of microglial states in AD hippoc54%

related🧫bEV-mediated synaptic pruning via C1q-C3 pathway54%

related🧫AhR agonist effects on NEP expression in N2a cells54%

related🧫AhR transcriptional regulation of NEP gene54%

related🧫GWAS of plasma GFAP in East Asian cohort54%

related🧫AhR agonist effects on NEP in APP/PS1 mice54%

related🧫Abeta-induced cell death and aggregation in GD3S-deficient n54%

related🧫bEV isolation and LPS quantification from human samples54%

related🧫Cerebral blood flow regulation in CD2AP mutant mice54%

related🧫Meta-analysis of physical activity interventions on cognitiv54%

related🧫Single-nucleus RNA-seq integration analysis54%

related🧫Generation of Aβ-specific Tregs using CRISPR-Cas954%

related🧫qPCR and western blot analysis of microvascular functional m54%

related🧫Reelin glycoprotein treatment rescue experiment54%

related🧫bEV extraction and analysis from mouse samples54%

related🧫KEEPS Continuation: Long-term effects of menopausal hormone 54%

related🧫Summary-based Mendelian randomization analysis54%

related🧫Anti-ASC antibody intracerebroventricular injection in APP/P54%

related🧫ASC antibody treatment in SH-SY5Y-APP695 cells54%

related🧫s:** - Test whether HCN1 knockout specifically in EC layer I54%

related🧫Proposed experiment from debate on Synaptic pruning by micro54%

related🧫Tet2 expression analysis in aged 2×Tg-AD mouse brains54%

related🧫Morphological characterization of microglial states in human54%

related🧫Microglial SIRPα expression in human Alzheimer's diseas54%

related🧫APOE4 association with TDP-43 pathology in AD54%

related🧫Microglial activation by bEVs via Piezo154%

related🧫Curcumin-Licorice Combination in D-galactose/Sodium Nitrite 54%

related🧫Cerebrovascular function analysis in CD2AP mutant mice54%

related🧫CD2AP loss association with cognitive decline in AD patients54%

related🧫TDP-43 pathology prevalence and distribution in AD cases54%

related🧫Brain Connectivity-Targeted tACS Trial in Early AD54%

related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 54%

related🧫4R-Tau Targeting Therapies for PSP and CBS54%

related🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi54%

related🧫AD Combination Therapy Trial: Anti-Aβ + Anti-Tau54%

related🧫Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti54%

related🧫Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?54%

related🧫Animal Model Comparison for Neurodegenerative Disease Therap54%

related🧫Anti-Tau Immunotherapy Dosing Optimization54%

related🧫ApoE4 Function in Alzheimer's Disease54%

related🧫Experiment: Autoimmune Hypothesis Testing in AD54%

related🧫Autophagy Enhancement Drug Screening for Neurodegeneration54%

related🧫Biomarker-Guided Sequential Therapy Selection in Alzheimer&#54%

related🧫Blood-Based Biomarker Panel for Early AD Detection54%

related🧫tACS Connectivity Trial in Early Alzheimer's54%

related🧫Brain Connectivity-Targeted tACS Trial in Early AD54%

related🧫Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated 54%

related🧫Cognitive Reserve Mechanisms in Alzheimer's Disease — M54%

related🧫Down Syndrome Alzheimer's Disease: Mechanisms and Thera54%

related🧫Epigenetic Regulation Dysfunction in Alzheimer's and Pa54%

related🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation54%

related🧫Gap Junction Dysfunction Validation in Parkinson's Dise54%

related🧫Lifestyle Intervention Mechanisms in Alzheimer's Diseas54%

related🧫Metal Ion Homeostasis Dysregulation in Alzheimer's Dise54%

related🧫Microbiome-Gut-Brain Axis in Alzheimer's Disease — mech54%

related🧫Microglial Aging and Immune Memory in Neurodegeneration — Tr54%

related🧫Migraine Cortical Hyperexcitability and Alzheimer's Dis54%

related🧫Mixed Pathology Effects on Parkinson's Disease Progress54%

related🧫Neural Stem Cell Therapy for Alzheimer's Disease54%

related🧫Normal Aging to Alzheimer's Disease Transition Trigger 54%

related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 54%

related🧫Prion Strain Diversity and Selective Vulnerability54%

related🧫SCFA-Mediated Neuroinflammation in Alzheimer's Disease54%

related🧫Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer&#54%

related🧫Sex Differences in Alzheimer's Disease — mechanisms and54%

related🧫Sleep Disruption and Alzheimer's Disease — mechanism an54%

related🧫Traumatic Brain Injury and Alzheimer's Disease Relation54%

related🧫Experiment Validation: In vitro ThT Assay54%

related🧫Tau ASO Therapy54%

related🧫Microglial TREM2 Agonist In Vivo Efficacy54%

related🧫TREM2 Function in Alzheimer's Disease — From Risk Varia54%

related🧫Vascular Contribution to Alzheimer's Disease — Beyond A54%

related🧫Vascular Contributions to Alzheimer Disease and Mixed Pathol54%

related🧫Viral Infections and Alzheimer's Disease — causal mecha54%

related🧫Longitudinal TLR2 reporter gene study in α-synuclein mice54%

related🧫iPSC-derived astrocyte-neuron co-culture mitochondrial trans54%

related🧫TLR expression in α-synuclein overexpressing mice54%

related🧫TLR expression analysis in Parkinson's disease patients54%

related🧫Dexamethasone treatment study in α-synuclein mice54%

related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera54%

related🧫AAV-LRRK2 IND-Enabling Study Design54%

related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD54%

related🧫Alpha-Synuclein SAA Kinetics Study — Biological Staging Back54%

related🧫Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio54%

related🧫Computational Modeling of Alpha-Synuclein Propagation in PD54%

related🧫Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation54%

related🧫Alpha-Synuclein Seed Amplification Assay Validation54%

related🧫Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation54%

related🧫Antiviral Therapy Trial for Parkinson's Disease54%

related🧫Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson&54%

related🧫Axonal Transport Dysfunction Validation in Parkinson's 54%

related🧫cGAS-STING Pathway Validation Study in Parkinson's Dise54%

related🧫Chaperone-Mediated Autophagy Dysfunction in PD - Experiment 54%

related🧫Combination Therapy Sequencing in Parkinson's Disease54%

related🧫CRISPR Gene Correction Approaches for CBS/PSP54%

related🧫DNA Damage Repair Deficiency Validation Study in Parkinson&#54%

related🧫Mechanism: Selective Vulnerability of Dopaminergic Neurons i54%

related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#54%

related🧫Epigenetic Dysregulation Validation in Parkinson's Dise54%

related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De54%

related🧫Exercise-BDNF-Mitophagy Biomarker Study in PD54%

related🧫Ferroptosis Validation in Parkinson's Disease54%

related🧫GLP-1 Agonist Neuroprotection Mechanism in PD54%

related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&54%

related🧫Gut-Brain Axis Pathogenesis in Parkinson's Disease — Me54%

related🧫Cytochrome Therapeutics54%

related🧫Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson54%

related🧫Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown54%

related🧫AAV-LRRK2 Gene Therapy IND-Enabling Study Design54%

related🧫LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne54%

related🧫Macroautophagy Dysfunction in PD - Experiment Design54%

related🧫Validate Mitochondria-Lysosome Contact Site Dysfunction in P54%

related🧫Validation: Membrane-Nucleation in iPSC Neurons54%

related🧫Metabolic Syndrome-Parkinson's Disease Axis Clinical Tr54%

related🧫Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in 54%

related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag54%

related🧫MLCS Quantification in Parkinson's Disease54%

related🧫Experiment: Multi-Ethnic PD GWAS54%

related🧫Multiscale Computational Modeling of Protein Aggregation Kin54%

related🧫Neural Oscillation Dysfunction Validation in Parkinson'54%

related🧫NLRP3 Inflammasome Validation Study in Parkinson's Dise54%

related🧫Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper54%

related🧫Non-Motor Symptom Progression in Parkinson's Disease — 54%

related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#54%

related🧫Parkinson's Disease Subtype Classification — Precision 54%

related🧫Peroxisomal Dysfunction Validation in Parkinson's Disea54%

related🧫Peroxisome Dysfunction Validation in Parkinson's Diseas54%

related🧫Prodromal Parkinson's Disease Biomarker Development — E54%

related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin54%

related🧫Purinergic Signaling Dysfunction Validation in Parkinson54%

related🧫Regulated Necrosis Validation Study in Parkinson's Dise54%

related🧫Sirtuin Dysfunction Validation in Parkinson's Disease54%

related🧫Sirtuin Pathway Dysfunction Validation in Parkinson's D54%

related🧫Stress Granule Dysfunction Validation in Parkinson's Di54%

related🧫Synaptic Mitochondrial Resilience Enhancement for Parkinson&54%

related🧫Synaptic Vesicle Trafficking Dysfunction Validation in Parki54%

related🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim54%

mentions🧪HSP90-Tau Disaggregation Complex Enhancement50%

mentions🧪VCP-Mediated Autophagy Enhancement50%

mentions🧪LRP1-Dependent Tau Uptake Disruption50%

mentions🧪Extracellular Vesicle Biogenesis Modulation50%

mentions🧪Synaptic Vesicle Tau Capture Inhibition50%

mentions🧪TREM2-mediated microglial tau clearance enhancement50%

mentions🧪Trans-Synaptic Adhesion Molecule Modulation50%

mentions🔬SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas50%

mentions🧪TREM2 Conformational Stabilizers for Synaptic Discrimination50%

mentions🧪APOE-TREM2 Interaction Modulation50%

mentions🧪TREM2-Mediated Selective Aggregate Clearance Pathway50%

mentions🧪TREM2-Dependent Microglial Senescence Transition50%

mentions🧪APOE Isoform Conversion Therapy50%

mentions🧪APOE4 Allosteric Rescue via Small Molecule Chaperones50%

mentions🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction50%

mentions🧪Targeted APOE4-to-APOE3 Base Editing Therapy50%

mentions🧪APOE4-Selective Lipid Nanoemulsion Therapy50%

mentions🧪Low Complexity Domain Cross-Linking Inhibition50%

mentions🧪Cross-Seeding Prevention Strategy50%

mentions🧪Extracellular Matrix Stiffness Modulation50%

mentions🧪Matrix Stiffness Normalization via Targeted Lysyl Oxidase In50%

related🔬What are the mechanisms underlying tdp-43 phase separation t50%

related🔬What are the mechanisms underlying astrocyte reactivity subt50%

related🔬What are the mechanisms underlying blood-brain barrier trans50%

related🔬What are the mechanisms underlying microglia-astrocyte cross50%

related🔬What are the mechanisms underlying apoe4 structural biology 50%

related🔬What are the mechanisms underlying rna binding protein dysre50%

related🔬What are the mechanisms underlying perivascular spaces and g50%

related🔬Analyze circuit-level changes in neurodegeneration using All50%

related🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc50%

related🔬Investigate prion-like spreading of tau pathology through co50%

related🔬SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas50%

related🔬The disease-associated microglia (DAM) phenotype involves TR50%

related🔬What are the mechanisms underlying tdp-43 phase separation t50%

related🔬What are the mechanisms underlying astrocyte reactivity subt50%

related🔬What are the mechanisms underlying blood-brain barrier trans50%

related🔬What are the mechanisms underlying microglia-astrocyte cross50%

related🔬What are the mechanisms underlying apoe4 structural biology 50%

related🔬What are the mechanisms underlying autophagy-lysosome pathwa50%

related🔬What are the mechanisms underlying what are the mechanisms b50%

related🔬What are the mechanisms underlying protein aggregation cross50%

related🔬What are the mechanisms underlying rna binding protein dysre50%

related🔬What are the mechanisms underlying perivascular spaces and g50%

related🔬Analyze circuit-level changes in neurodegeneration using All50%

related🔬The disease-associated microglia (DAM) phenotype involves TR50%

related🔬Is disrupted sleep a cause or consequence of neurodegenerati50%

related🔬What gene expression changes in the aging mouse brain predic50%

related🔬Comprehensive analysis of immune cell subtypes in neurodegen50%

related🔬What cell types are most vulnerable in Alzheimers Disease ba50%

related🔬What cell types are most vulnerable in Alzheimer's Dise50%

related🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc50%

related🔬Investigate prion-like spreading of tau pathology through co50%

related🔬How does metabolic reprogramming (glucose metabolism shifts,50%

related🔬SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas50%

related🔬What are the most promising therapeutic strategies for targe50%

related🔬How to break the GBA-alpha-synuclein bidirectional loop for 50%

related🔬Can gut-brain axis modulation prevent or slow Alzheimer'50%

related🔬Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph50%

related🧪Microbial Metabolite-Mediated α-Synuclein Disaggregation50%

see_also📖SLC16A1 — Solute Carrier Family 16 Member 1 (Monocarboxylate50%

see_also📖C1QA Gene50%

see_also📖slc17a7 Gene50%

see_also📖Agitation in Alzheimer's Disease50%

see_also📖Alzheimer's Disease50%

see_also📖Alzheimer's Disease Genetic Variants50%

see_also📖Alzheimer's Disease vs Parkinson's Disease Compari50%

see_also📖APP Mutations in Alzheimer's Disease50%

see_also📖Early-Onset Alzheimer's Disease (EOAD)50%

see_also📖Investment Landscape: Alzheimer's Disease50%

see_also📖Preclinical Alzheimer's Disease50%

see_also📖Prodromal Alzheimer's Disease50%

see_also📖PSEN1 Mutations in Alzheimer's Disease50%

see_also📖PSEN2 Mutations in Alzheimer's Disease50%

see_also📖Sporadic vs Familial Alzheimer's Disease: Comprehensive50%

see_also📖TREM2 Variants in Alzheimer's Disease50%

see_also📖CHMP4B — Charged Multivesicular Body Protein 4B50%

see_also📖SST Gene50%

see_also📖HSP90AA1 Gene50%

see_also📖PVALB Gene - Parvalbumin50%

see_also📖Shared Mechanisms Between Alzheimer and Parkinson Disease50%

see_also📖Blood-Brain Barrier Dysfunction and Therapeutic Delivery for50%

see_also📖C9orf72 Repeat Expansions in CBS and PSP50%

see_also📖Myoclonus and Cortical Hyperexcitability in Corticobasal Syn50%

see_also📖FTLD-TDP Subtypes and Mechanisms50%

see_also📖mTOR Signaling in Autophagy and Lysosomal Function50%

see_also📖Neuroinflammation in Parkinson's Disease Dementia and D50%

see_also📖Neuroresilience Mechanisms and Evidence50%

see_also📖Advanced Proteolysis and Ubiquitin System Targeting in CBS/P50%

see_also📖HLA Haplotypes and Neuroinflammatory Profiles in PSP50%

see_also📖Synaptic Loss and Dysfunction Pathway50%

see_also📖Systemic Infection and Tau Pathology Acceleration50%

see_also📖Tau Seeding and Propagation Pathway50%

see_also📖AAIC 2026: Tau-PET Imaging and Fluid Biomarker Integration45%

see_also📖Alpha-Synuclein PET Imaging and Biomarker Advances45%

see_also📖Alpha-Synuclein Seeding Assays (RT-QuIC and PMCA)45%

see_also📖Imaging Biomarkers for Corticobasal Syndrome and Progressive45%

see_also📖Multi-Analyte Biomarker Panel for Parkinson's Disease D45%

see_also📖Polygenic Risk Score Integration Panel for Alzheimer's 45%

see_also📖CSF and Blood Biomarkers in Progressive Supranuclear Palsy45%

see_also📖p-Tau Biomarker in Immunoglobulin Light Chain and Transthyre45%

see_also📖BLAAC PD - Black and African Americans Connections to PD (NC45%

see_also📖Clostridium Butyricum for Motor and Non-motor Symptoms in Pa45%

see_also📖CNversyt and Megan Rodden ALS Trials45%

see_also📖Cognitive and Speech Rehabilitation in CBS (NCT05823421)45%

see_also📖Digital Therapeutic Platform for Swallowing and Drooling Pro45%

see_also📖First-in-Human 4R Tau Ligand Study in PSP (NCT07348276)45%

see_also📖Gait Analysis Parameter and Upper Limb Evaluation in Neurolo45%

see_also📖Gait and Upper Limb Evaluation in PSP (NCT07136844)45%

see_also📖GBA Brain Molecular Imaging and Blood Biomarkers for Precisi45%

see_also📖Utilisation of Health Services and Quality of Life in Atypic45%

see_also📖Phase 3 Study to Compare the Efficacy and Safety of Masitini45%

see_also📖LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for APOE45%

see_also📖Safety and Clinical Outcomes Study: Amniotic and Umbilical C45%

see_also📖A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, M45%

see_also📖A Phase III, Randomized, Double-Blind, Placebo-Controlled, M45%

see_also📖A Multicenter, Phase III, Randomized, Double Blind, Placebo-45%

see_also📖A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-C45%

see_also📖Long-term Effects of Hearing Intervention on Brain Health in45%

see_also📖A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial45%

see_also📖A 6-month & 18-month Prospective, Randomized, Placebo-co45%

see_also📖A Phase 3, Randomized, Double-blind, Placebo-controlled, Par45%

see_also📖PCDH19-Related Epilepsy (EFMR) — Preclinical Gene Therapy Pr45%

see_also📖Whole-Body Photobiomodulation for Motor and Cognitive Change45%

see_also📖PI-2620 Tau PET Phase 3 (NCT05456503) - FTLD and Atypical AD45%

see_also📖Quality of Life and Caregiver Burden in PSP (NCT03638505)45%

see_also📖Silymarin for Neuroprotection and Symptom Management in Park45%

see_also📖Social Behaviors and Quality of Life in Parkinson's Dis45%

see_also📖Clinical Efficacy and Mechanism of tDCS for Dysphagia in Par45%

see_also📖alexander-disease45%

see_also📖Alexander Disease Genetic Variants45%

see_also📖Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pi45%

see_also📖APOE4 (Apolipoprotein E4)45%

see_also📖ATP13A9 and Parkinson's Disease45%

see_also📖Callosal Disconnection and Interhemispheric Dysfunction in C45%

see_also📖CARASIL (Cerebral Autosomal Recessive Arteriopathy with Subc45%

see_also📖Caregiver Burden and Support in Corticobasal Syndrome45%

see_also📖Caregiver Support and Palliative Care in Atypical [Parkinson45%

see_also📖Clinical Phenotypes and Subtypes of Corticobasal Syndrome45%

see_also📖Natural History and Prognosis of Corticobasal Syndrome45%

see_also📖Dysphagia and Nutritional Management in Corticobasal Syndrom45%

see_also📖Environmental Toxins and Parkinson's Risk45%

see_also📖HIV-Associated Neurocognitive Disorders (HAND)45%

see_also📖Hemiballismus and Hemichorea in Corticobasal Syndrome45%

see_also📖Hereditary Sensory and Autonomic Neuropathy (HSAN)45%

see_also📖Investment Landscape: ALS45%

see_also📖Investment Landscape: Frontotemporal Dementia45%

see_also📖Investment Landscape: Huntington's Disease45%

see_also📖Investment Landscape: Parkinson's Disease45%

see_also📖Japanese and German Case Series in Corticobasal Degeneration45%

see_also📖Jervell and Lange-Nielsen Syndrome45%

see_also📖LRRK2 Gene Variants and Mutations45%

see_also📖MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acid45%

see_also📖Mirror Therapy and Sensory Re-education in Corticobasal Synd45%

see_also📖Nutritional Support and Dietary Interventions in Corticobasa45%

see_also📖Physical and Occupational Therapy in Corticobasal Syndrome45%

see_also📖Postural Dysfunction and Abnormalities in Corticobasal Syndr45%

see_also📖Pseudobulbar Affect and Emotional Lability in Corticobasal S45%

see_also📖Healthcare Economics and Cost of Illness in Progressive Supr45%

see_also📖PSP and Idiopathic Normal Pressure Hydrocephalus: Clinical O45%

see_also📖Quality of Life and Caregiver Burden in Progressive Supranuc45%

see_also📖Speech and Voice Disorders in PSP45%

see_also📖Sandhoff Disease45%

see_also📖Sialorrhea and Drooling in Corticobasal Syndrome45%

see_also📖Simultanagnosia and Balint's Syndrome in Corticobasal S45%

see_also📖SNCA Gene Variants and Mutations45%

see_also📖Speech Therapy and Communication Aids in Corticobasal Syndro45%

see_also📖Vocational Rehabilitation and Driving in Corticobasal Syndro45%

see_also📖Voice and Speech in Corticobasal Syndrome45%

see_also📖ALS Biomarkers and Disease Monitoring45%

see_also📖Braak Staging and Tau Propagation Pathway45%

see_also📖Multimodal Diagnostic Algorithm for CBS and PSP45%

see_also📖CBS/PSP Panxoneopathy and Membrane Biology45%

see_also📖VEGF and Angiogenesis Dysregulation in CBS/PSP45%

see_also📖Pupillometry and Chromatic Pupillometry in Corticobasal Synd45%

see_also📖FTDP-17 Clinical Phenotypes and Disease Progression45%

see_also📖GBA Glucocerebrosidase Dysfunction and Parkinson's Dise45%

see_also📖Glial Tau Pathology in PSP and CBD45%

see_also📖Glymphatic Clearance Hypothesis — Impaired Aβ and Tau Remova45%

see_also📖Glymphatic and Vascular Clearance Dysfunction in 4R-Tauopath45%

see_also📖Iron and Neuromelanin Accumulation in PSP45%

see_also📖LRRK2 Kinase Activation and Endolysosomal Dysfunction in Par45%

see_also📖MSA Clinical Features and Diagnosis45%

see_also📖NLRP3 Inhibitors in Parkinson's Disease: Research and C45%

see_also📖Pesticides and Parkinson Disease (Pest-PD) — NCT0642031045%

see_also📖Gait and Balance Disorders in Progressive Supranuclear Palsy45%

see_also📖PSP Liquid-Liquid Phase Separation and Biomolecular Condensa45%

see_also📖PSP Lysosomal Dysfunction and Autophagy Impairment45%

see_also📖Metabolic Dysfunction and Insulin Resistance in Progressive 45%

see_also📖Pupillary and Visual Dysfunction in Progressive Supranuclear45%

see_also📖PSP Tau Propagation and Spreading Mechanisms45%

see_also📖PSP Weight Loss and Cachexia45%

see_also📖Sleep Architecture Changes in CBS and PSP45%

see_also📖Somatic Mutations and Brain Mosaicism45%

see_also📖Speech and Language Deficits in Corticobasal Syndrome45%

see_also📖TBK1 Autophagy and Neuroinflammation ALS/FTD Causal Chain45%

see_also📖ALS Therapeutic Landscape — Programs by Phase and Modality45%

mentions🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc40%

mentions🔬What cell types are most vulnerable in Alzheimer's Dise40%

mentions🔬What are the most promising therapeutic strategies for targe40%

mentions🔬Can gut-brain axis modulation prevent or slow Alzheimer'40%

mentions🔬What cell types are most vulnerable in Alzheimers Disease ba40%

mentions🔬What gene expression changes in the aging mouse brain predic40%

mentions🔬How to break the GBA-alpha-synuclein bidirectional loop for 40%

mentions🔬What are the mechanisms underlying protein aggregation cross40%

mentions🔬The disease-associated microglia (DAM) phenotype involves TR40%

mentions🔬Is disrupted sleep a cause or consequence of neurodegenerati40%

mentions🔬Comprehensive analysis of immune cell subtypes in neurodegen40%

mentions🔬Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph40%

mentions🔬What are the mechanisms underlying autophagy-lysosome pathwa40%

mentions🔬How does metabolic reprogramming (glucose metabolism shifts,40%

mentions🔬What are the mechanisms underlying what are the mechanisms b40%

related🧪HSP90-Tau Disaggregation Complex Enhancement40%

related🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer40%

related🧪VCP-Mediated Autophagy Enhancement40%

related🧪LRP1-Dependent Tau Uptake Disruption40%

related🧪Extracellular Vesicle Biogenesis Modulation40%

related🧪Low Complexity Domain Cross-Linking Inhibition40%

related🧪Extracellular Matrix Stiffness Modulation40%

related🧪Synaptic Vesicle Tau Capture Inhibition40%

related🧪Matrix Stiffness Normalization via Targeted Lysyl Oxidase In40%

related🧪TREM2-mediated microglial tau clearance enhancement40%

related🧪Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides40%

related🧪Competitive APOE4 Domain Stabilization Peptides40%

related🧪Cross-Seeding Prevention Strategy40%

related🧪Trans-Synaptic Adhesion Molecule Modulation40%

related🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia40%

related🧪GFAP-Positive Reactive Astrocyte Subtype Delineation40%

related🧪Complement C1QA Spatial Gradient in Cortical Layers40%

related🧪Excitatory Neuron Vulnerability via SLC17A7 Downregulation40%

related🧪APOE Isoform Expression Across Glial Subtypes40%